問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Psychiatry

更新時間：2023-09-19

劉震鐘Liu, Chen-Chung
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

7Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉震鐘

List

17Cases

2019-07-15 - 2020-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2010-09-01 - 2012-12-31

Phase III

A multicenter, randomized, double-blind, fixed-dose, 6-week trial of the efficacy and safety of asenapine compared with placebo in subjects with an acute exacerbation of schizophrenia (Phase 3 ; Protocol No. P06124)

  • Condition/Disease

    Schizophrenia

  • Test Drug

    Asenapine (SCH 900274)

Participate Sites
13Sites

Terminated13Sites

黃宗正
National Taiwan University Hospital

Division of Psychiatry

2020-12-15 - 2022-06-30

Phase III

A Phase 3, multi-center, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy and safety of sodium oligomannate (GV-971) in treatment of mild to moderate Alzheimer’s disease (GREEN MEMORY: GREen Valley 971 EvaluatioN Memory)

  • Condition/Disease

    Alzheimer’s disease

  • Test Drug

    GV-971

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting1Sites

Terminated1Sites

2012-09-01 - 2016-02-28

Phase III

Long-term Extension Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia <Phase 3>

  • Condition/Disease

    Schizophrenia

  • Test Drug

    SM-13496

Participate Sites
8Sites

Terminated8Sites

黃宗正
National Taiwan University Hospital

Division of Psychiatry

2012-08-01 - 2015-08-31

Phase III

Randomized, Double-blind, Parallel- group, Placebo-controlled, Confirmatory Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia <Phase 3>

  • Condition/Disease

    schizophrenia

  • Test Drug

    SM-13496

Participate Sites
13Sites

Terminated13Sites

黃宗正
National Taiwan University Hospital

Division of Psychiatry

2019-08-01 - 2021-04-14

Phase II

A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 28-week treatment period as adjunctive therapy to antipsychotic treatment for the prevention of relapse in patients with schizophrenia.

  • Condition/Disease

    Schizophrenia

  • Test Drug

    BI 409306

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

2018-05-04 - 2020-12-31

Phase II

A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patients with Schizophrenia

  • Condition/Disease

    Patients with established Schizophrenia (as per DSM-5) who are clinically stable

  • Test Drug

    BI 425809

Participate Sites
4Sites

Terminated4Sites

黃宗正
National Taiwan University Hospital

Division of Psychiatry

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB